Cargando…

Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL

SIMPLE SUMMARY: In general, the non-Hodgkin lymphoma (NHL), anaplastic large cell lymphoma (ALCL) diagnosed in childhood has a good survival outcome when treated with multi-agent chemotherapy. However, side effects of treatment are common, and outcomes are poorer after relapse, which occurs in up to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hare, Lucy, Burke, G. A. Amos, Turner, Suzanne D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656581/ https://www.ncbi.nlm.nih.gov/pubmed/34885113 http://dx.doi.org/10.3390/cancers13236003

Ejemplares similares

Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond
por: Prokoph, Nina, et al.
Publicado: (2018)

P1235: INVESTIGATION OF THE CO-MUTATIONAL LANDSCAPE OF ALK-POSITIVE ALCL
por: Villa, Matteo, et al.
Publicado: (2023)

The heterogeneous landscape of ALK negative ALCL
por: Mereu, Elisabetta, et al.
Publicado: (2017)

BRG1 and NPM-ALK Are Co-Regulated in Anaplastic Large-Cell Lymphoma; BRG1 Is a Potential Therapeutic Target in ALCL
por: Garland, Gavin D., et al.
Publicado: (2021)

The Dual Role of Autophagy in Crizotinib-Treated ALK(+) ALCL: From the Lymphoma Cells Drug Resistance to Their Demise
por: Espinos, Estelle, et al.
Publicado: (2021)

ALK+ ALCL in the setting of adalimumab‐related hidradenitis suppurativa
por: Craig, Alexander, et al.
Publicado: (2023)

Revealing the true face behind the mask of ALK-positive anaplastic large cell lymphoma (ALCL)
por: Eisfeld, Hannah, et al.
Publicado: (2020)

PB2372: PP2A INHIBITOR LB100 ENHANCES THE SENSITIVITY OF NPM-ALK+ALCL TO CRIZOTINIB AND REVERSES THE RESISTANCE OF ALCL TO CRIZOTINIB
por: Shi, Wenyu
Publicado: (2023)

Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
por: Damm-Welk, Christine, et al.
Publicado: (2016)

ALK+ Anaplastic Large Cell Lymphoma (ALCL)-Derived Exosomes Carry ALK Signaling Proteins and Interact with Tumor Microenvironment
por: Chioureas, Dimitrios, et al.
Publicado: (2022)

Expression of granzyme B sensitizes ALK+ ALCL tumour cells to apoptosis-inducing drugs
por: Pearson, Joel D, et al.
Publicado: (2014)

STAT3 Mutation Is Associated with STAT3 Activation in CD30(+) ALK(−) ALCL
por: Andersson, Emma I., et al.
Publicado: (2020)

De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells
por: Babin, Loélia, et al.
Publicado: (2022)

Erratum to: ‘Expression of granzyme B sensitizes ALK+ ALCL tumour cells to apoptosis-inducing drugs’
por: Pearson, Jodel D., et al.
Publicado: (2016)

Primary Cutaneous CD30+/ALK- ALCL with Transition into sALCL: Favourable Response after Systemic Administration with Brentuximab Vedotin! Unique Presentation in a Bulgarian Patient!
por: Popova, Tanya Naskova, et al.
Publicado: (2018)

Anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma (ALCL) of breast in a patient without a breast implant
por: Sathyanarayanan, Vishwanath, et al.
Publicado: (2014)

The DNA-helicase HELLS drives ALK(−) ALCL proliferation by the transcriptional control of a cytokinesis-related program
por: Tameni, Annalisa, et al.
Publicado: (2021)

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
por: Isozaki, Hideko, et al.
Publicado: (2015)

Identification of C/EBPβ Target Genes in ALK+ Anaplastic Large Cell Lymphoma (ALCL) by Gene Expression Profiling and Chromatin Immunoprecipitation
por: Bonzheim, Irina, et al.
Publicado: (2013)

CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL
por: Montes-Mojarro, Ivonne-Aidee, et al.
Publicado: (2022)

From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL)
por: Werner, Michael T., et al.
Publicado: (2017)

Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK(+) ALCL: results of COG trial ANHL12P1
por: Lowe, Eric J., et al.
Publicado: (2021)

Next-Generation Sequencing Identifies Deregulation of MicroRNAs Involved in Both Innate and Adaptive Immune Response in ALK+ ALCL
por: Steinhilber, Julia, et al.
Publicado: (2015)

Phosphorylated STAT3 as a potential diagnostic and predictive biomarker in ALK(-) ALCL vs. CD30(high) PTCL, NOS
por: Xiang, Chenxi, et al.
Publicado: (2023)

BIA-ALCL-Horizon Scanning
por: Mallucci, Patrick, et al.
Publicado: (2022)

AGENT ORANGE‐INDUCED Anaplastic Large‐Cell Lymphoma (ALCL) with Cutaneous Involvement
por: Lorio, Morgan, et al.
Publicado: (2021)

Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial
por: Mussolin, Lara, et al.
Publicado: (2020)

An Exploration into the Origins and Pathogenesis of Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase (ALK)-Positive
por: Turner, Suzanne D.
Publicado: (2017)

EBP2, a novel NPM‐ALK‐interacting protein in the nucleolus, contributes to the proliferation of ALCL cells by regulating tumor suppressor p53
por: Uchihara, Yuki, et al.
Publicado: (2020)

AP-1 family transcription factors: a diverse family of proteins that regulate varied cellular activities in classical hodgkin lymphoma and ALK+ ALCL
por: Wu, Zuoqiao, et al.
Publicado: (2021)

The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status
por: Trigg, Ricky M., et al.
Publicado: (2019)

NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma
por: Haque, Moinul, et al.
Publicado: (2019)

A Multidimensional Investigation of BIA-ALCL and Systemic ALCL Proliferation Rates in Response to Silicone Implant Shells and the Breast Microenvironment
por: Ann Askinas, Carly, et al.
Publicado: (2022)

Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma
por: Wang, Yuan, et al.
Publicado: (2022)

Primary Anaplastic Lymphoma Kinase (ALK)-Negative Anaplastic Large Cell Lymphoma (ALCL) Presenting as Perforation Peritonitis: A Case Report and Management Principles
por: Sanker, Vivek, et al.
Publicado: (2022)

Etiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Current Directions in Research
por: Deva, Anand K., et al.
Publicado: (2020)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

Fundamental features of AlCl(4)(−)-/AlCl(4)-graphite intercalation compounds of aluminum-ion-based battery cathodes
por: Li, Wei-Bang, et al.
Publicado: (2022)

Case Report: A recurrent case of ALK-ALCL after autologous transplantation was successfully treated with BV + a modified CHEP chemotherapy containing mitoxantrone hydrochloride liposome with the addition of chidamide maintenance therapy
por: Shang, Zhen, et al.
Publicado: (2023)

Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer
por: Lovly, Christine M., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9d19dqnlrd2aj5gl48pp2bvgi2